Below are the most recent publications written about "Hypoglycemic Agents" by people in Profiles.
-
Malin SK, Braun B. Are we closer to providing better guidance for prescribing metformin and exercise to patients? Obesity (Silver Spring). 2022 06; 30(6):1141-1142.
-
Raza A, Murtaza SH, Hanif S, Iqbal J, Ali I, Aftab T, Shakir R, Bedar R, Syed MA. Validation of a rapid and economical RP-HPLC method for simultaneous determination of metformin hydrochloride and sitagliptin phosphate monohydrate: Greenness evaluation using AGREE score. Pak J Pharm Sci. 2022 Jan; 35(1):15-21.
-
Yang X, Dai J, Zhong Y, Wei X, Wu M, Zhang Y, Huang A, Wang L, Huang Y, Zhang C, Chen X, Xiao H. Characterization of insoluble dietary fiber from three food sources and their potential hypoglycemic and hypolipidemic effects. Food Funct. 2021 Jul 21; 12(14):6576-6587.
-
Gourgari E, Huerta-Saenz L, Tonyushkina KN, Rosolowsky ET, Guttmann-Bauman I. Use of glucagon-like peptide-1 receptor agonists for pediatric patients with obesity and diabetes: The providers' perspectives. Pediatr Diabetes. 2021 09; 22(6):872-875.
-
Chang HY, Chou YY, Tang W, Chang GM, Hsieh CF, Singh S, Tung YC. Association of antidiabetic therapies with lower extremity amputation, mortality and healthcare cost from a nationwide retrospective cohort study in Taiwan. Sci Rep. 2021 03 26; 11(1):7000.
-
Barry K, Slawson DC, Shaughnessy AF. Evidence to Avoid Overtesting and Overuse in Diabetes Mellitus and Other Diseases. Am Fam Physician. 2020 11 15; 102(10):583-584.
-
Böhme J, Martinez N, Li S, Lee A, Marzuki M, Tizazu AM, Ackart D, Frenkel JH, Todd A, Lachmandas E, Lum J, Shihui F, Ng TP, Lee B, Larbi A, Netea MG, Basaraba R, van Crevel R, Newell E, Kornfeld H, Singhal A. Metformin enhances anti-mycobacterial responses by educating CD8+ T-cell immunometabolic circuits. Nat Commun. 2020 10 16; 11(1):5225.
-
Thielen LA, Chen J, Jing G, Moukha-Chafiq O, Xu G, Jo S, Grayson TB, Lu B, Li P, Augelli-Szafran CE, Suto MJ, Kanke M, Sethupathy P, Kim JK, Shalev A. Identification of an Anti-diabetic, Orally Available Small Molecule that Regulates TXNIP Expression and Glucagon Action. Cell Metab. 2020 09 01; 32(3):353-365.e8.
-
Shifrin M, Siegelmann H. Near-optimal insulin treatment for diabetes patients: A machine learning approach. Artif Intell Med. 2020 07; 107:101917.
-
Batista TM, Dagdeviren S, Carroll SH, Cai W, Melnik VY, Noh HL, Saengnipanthkul S, Kim JK, Kahn CR, Lee RT. Arrestin domain-containing 3 (Arrdc3) modulates insulin action and glucose metabolism in liver. Proc Natl Acad Sci U S A. 2020 03 24; 117(12):6733-6740.